What Tempus AI (TEM)'s Military Cancer Care Partnership Means For Shareholders

Simply Wall St.11-12 10:27

SOTERIA Precision Medicine Foundation recently disclosed a collaboration with Tempus AI to provide genomic sequencing, AI-driven cancer treatment insights, and precision oncology navigation for active...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682532183?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041","is_english":true,"pubTime":"2026-11-12 10:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682532183","market":"sg","top_or_hot":-1,"title":"What Tempus AI (TEM)'s Military Cancer Care Partnership Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>SOTERIA Precision Medicine Foundation recently disclosed a collaboration with Tempus AI to provide genomic sequencing, AI-driven cancer treatment insights, and precision oncology navigation for active...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/what-tempus-ai-tems-military-cancer-care-partnership-means-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Tempus AI (TEM)'s Military Cancer Care Partnership Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Tempus AI (TEM)'s Military Cancer Care Partnership Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-12 10:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/what-tempus-ai-tems-military-cancer-care-partnership-means-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SOTERIA Precision Medicine Foundation recently disclosed a collaboration with Tempus AI to provide genomic sequencing, AI-driven cancer treatment insights, and precision oncology navigation for active...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/what-tempus-ai-tems-military-cancer-care-partnership-means-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/what-tempus-ai-tems-military-cancer-care-partnership-means-f","article_id":"2682532183","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/what-tempus-ai-tems-military-cancer-care-partnership-means-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682532183","pubTimestamp":1794450431,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 12, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ARKG":"ARK Genomic Revolution ETF","BK4611":"AI医疗","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TEM":"Tempus AI","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4613":"AI应用软件","TEMC":"Corgi TEM 2x Daily ETF","TEMT":"2倍做多TEM ETF-Tradr","HEAL":"Global X HealthTech ETF"},"translate_title":"腾邦人工智能 (TEM) 的军事癌症护理合作伙伴关系对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEMT":0.6,"TEM":1.97,"ARKG":0.6,"TEMC":0.6,"HEAL":0.6},"content_text":"SOTERIA Precision Medicine Foundation recently disclosed a collaboration with Tempus AI to provide genomic sequencing, AI-driven cancer treatment insights, and precision oncology navigation for active-duty U.S. military personnel and veterans. By integrating a defined military and veteran cohort into Tempus AI's data and diagnostics platform, this partnership deepens the firm’s real-world evidence base and can reinforce demand for its precision oncology services across both testing and data products. We will now look at how Tempus AI’s expanded precision oncology role with SOTERIA affects the broader long term investment narrative.  Scan how Tempus AI’s military-focused precision oncology push compares with other specialized healthcare AI players by reviewing the hand-picked 36 healthcare AI stocks shaping this corner of the market. AdvertisementTempus AI Investment Narrative Recap To own Tempus AI, you need to believe the healthcare data flywheel that QuanD, an investor in the Simply Wall St Community, describes keeps compounding. Diagnostics feeds more multimodal records into the platform, which can support the Data and Applications segment. The SOTERIA partnership fits that view but does not obviously change the near term story on its own. Right now, the key near term catalyst is execution on revenue and the path toward consistent profitability. The latest military collaboration may support testing volume and data depth over time, while the main risk still sits with ongoing losses, higher risk funding, valuation pressure and a volatile share price if expectations slip. The third quarter update on 2 November 2026 looks most relevant. Tempus AI reported quarterly sales of US$303.47m and total revenue of US$411.54m, with the quarterly net loss narrowing to US$14.85m. For the first nine months of 2026, revenue reached US$1.142b and the loss for that period was US$135.13m. Management also raised full year 2026 revenue guidance to a range of US$1.60b to US$1.605b. This aligns with QuanD’s focus on the platform’s data driven growth potential. Hitting or missing that range now sits front and center as an operational catalyst, while any stumble could matter for a stock already flagged as expensive on P/S multiples. QuanD’s narrative reaches a fair value of US$75.68 for Tempus AI by assuming revenue compounds at 15% a year, the business reaches a 25% profit margin in future, and the resulting earnings stream supports that valuation, according to Simply Wall St’s Future Multiple Valuator framework. Uncover why Tempus AI's fair value indicates a 5% potential downside to its current price, which leaves little room for error. NasdaqGS:TEM 1-Year Stock Price Chart Exploring Other Perspectives Some of the most optimistic analysts frame Tempus AI’s collaboration with SOTERIA through a different lens. They focus on the revenue trajectory. Before this news, the bullish group was already modeling about 26.7% annual top line growth and revenue of roughly US$2.9b by 2029. That view assumes earnings of about US$472.8m and a P/E near 50x. If you prefer that narrative, you are effectively betting the new military data stream could strengthen an already ambitious path, or, if it disappoints, force those projections to be reset. It is worth comparing those upbeat assumptions with other opinions before deciding which story you find more convincing. Explore 4 other Tempus AI fair value estimates, including one that suggests up to 27% upside from the current price. Reach Your Own Conclusion Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your Tempus AI research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for Tempus AI. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Tempus AI's overall financial health at a glance.  Looking For More Ideas Beyond Tempus AI? Once you have formed a view on Tempus AI, it can help to widen the lens and compare it with other potential opportunities that suit different risk and income preferences.  If you want potential mispriced opportunities with quality traits, scan through a curated 32 high quality undervalued stocks that combine resilient cash flows with solid fundamentals. For readers who care most about capital preservation, consider a 30 resilient stocks with low risk scores that scores well on resilience and balance sheet strength. If you are hunting for future leaders early, review a 19 high quality undiscovered gems that pair strong underlying metrics with relatively low market attention.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tempus AI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682532183","isCrawlerRequest":true}